Corrects the Record Regarding Activist Group’s False and Misleading Statements

Highlights Evidence of Group’s Scheme to Have Jorgl Serve as the “Face of the Activist” to Help Them “Get Control” Without Paying a Premium to All Shareholders

Group Concealed that Its Campaign Was Orchestrated by One Convicted Felon and Financed by Another Criminal – Until Forced to Do So in Context of Litigation

Urges Shareholders to Continue to Support Company’s Positive Momentum Towards Value Creation by Voting on the WHITE Proxy Card to Re-Elect AIM’s Current Directors

The Board of Directors (“Board”) of AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”) today issued a letter to shareholders to correct the record around recent false and misleading statements made by Jonathan Jorgl and other members of an activist group, who have attempted to nominate two director candidates for election as directors at the Company’s 2022 Annual Meeting of Shareholders and are seeking to take control of the Board.

The full text of the letter follows:

October 26, 2022

Dear fellow shareholders:

We are writing to you today to set the record straight following the web of false and misleading statements made recently by a group of individuals that is trying to take control of the Board of Directors (the “Board”) of AIM ImmunoTech (the “Activist Group”). Key facts that the Activist Group is concealing include:

1. The fact that its campaign to gain control of AIM has been orchestrated by an individual – Franz Tudor – who has been convicted of insider trading and is being funded by another individual – Michael Xirinachs – who recently pled guilty to wire fraud.
2. After Tudor determined to seek control via a proxy contest and selected the director nominees, he and his nominees searched for someone to buy AIM stock and serve as the “face” of the effort because the Activist Group wanted to hide the involvement of criminals (i.e., Tudor and Xirinachs).
3. The Activist Group intends to potentially acquire AIM, merge it with another company or sell all or part of the Company.

Given that these facts only came out in the context of expedited litigation in which the Activist Group tried to prevent and evade discovery, shareholders should ask themselves what else this group may be hiding.

As you may know, our 2022 Annual Meeting of Shareholders (the “Annual Meeting”) is scheduled to be held on November 3, 2022. Jonathan Jorgl, the “face” of the Activist Group, who personally owns only 1,000 shares of AIM and purchased them in late June 2022, has attempted to nominate two director candidates – Robert Chioini and Michael Rice – for election to the Board at the Annual Meeting. If these two individuals were elected, they would control the Board and the Company.

Shareholders have the right to nominate director candidates for election to the Board, but are required to comply with AIM’s bylaws. Like many companies, AIM has bylaw provisions in place to ensure that shareholders nominating director candidates present sufficient information for the Board to assess the nominations and to allow other investors to make informed decisions when they vote. In this case, the Activist Group did not provide this required information and, alarmingly, appears to have concealed myriad facts about its actions, funding, associates and intentions.

After careful deliberation, the Board unanimously determined that these nominations did not comply with AIM’s bylaws and were invalid. Jorgl is attempting to fight this determination in a case currently pending before the Delaware Court of Chancery. On October 5, 2022, the Delaware Court held a hearing on Jorgl’s request for a preliminary injunction. The Court has not yet ruled, but the Company anticipates that the Court will be issuing its decision in advance of the Annual Meeting. Unless the result of the Delaware litigation is that the nominations are valid, all proxies submitted by the Activist Group at the Annual Meeting will be disregarded.

The Activist Group has cherry-picked and distorted information from the litigation discovery and has attempted to create a smokescreen to hide its true intentions. The Company believes the Activist Group is spreading misinformation about the Company, its directors and its progress, including through numerous misleading StockTwits posts by Tudor under his handle “beaufordb” (which he conceded during a deposition belongs to him). It is important that shareholders understand the truth and are not misled by those who do not share their interests.

Fortunately for all shareholders, a great deal of information has come to light as a result of the Activist Group’s lawsuit against the Company. These facts reveal the true picture:

• A convicted criminal, Franz Tudor, initiated the Activist Group campaign and selected the nominees,
• The campaign is being funded by another criminal, Michael Xirinachs, who recently pled guilty to wire fraud,
• Jorgl is merely serving as the “face” of the group to conceal the significant roles of the criminals, and
• The Activist Group has plans to take control of the Company’s Board for purposes at odds with the best interests of all shareholders.

Please consider the following:

The Activist Group’s Campaign Was Orchestrated by Undisclosed Individuals – Including Two Convicted Criminals – Who Have Been Trying to Take Control of AIM for Years

• From the start, Jorgl failed to disclose that he was making his nominations on behalf of and in concert with other individuals, including Tudor, Ted Kellner, Todd Deutsch and Walter Lautz – who had been conspiring for years to influence control of AIM and profit through stock manipulation efforts.

• Tudor is a convicted insider trader who has been improperly interfering with AIM’s business relations and seeking to disrupt AIM for approximately two years – ever since AIM declined his bid in 2020 to be hired as an international business development consultant to the Company. His harassment of AIM and attempts to interfere with its business relations became so extreme that AIM successfully obtained an injunction against Tudor in Marion County, Florida in August 2021.

• As early as December 2021, Tudor and Lautz were working to find an activist front man to remove AIM President, CEO and director Thomas Equels and the other members of the Board from AIM, as shown in their private communications:
  
  
  
  
  • “[T]his board needs to be ousted”
    
    
    
    
  • “[W]e need to find a way to get Tom [Equels] ousted”

• Prior to Jorgl submitting his nominations, Tudor worked with Lautz to present a proposal to AIM to nominate Chioini (later one of Jorgl’s nominees) and Daniel Ring as candidates for the Board. After that invalid proposal and its purported nominations were properly rejected, Tudor emailed AIM’s outside IR firm and said “you now get gloves off.”

Jorgl is Merely the “Face” of the Activist Group’s Campaign – Which is Financially Supported by Michael Xirinachs, Who Owns No AIM Stock and Recently Pled Guilty to Wire Fraud

• In his nomination notice, Jorgl did not include the true arrangements and motivations behind the nominations. Discovery in the Delaware litigation brought to light numerous items that were omitted.

• In early June 2022, Tudor sent an email to Deutsch stating that Tudor had two candidates “to run and get control of the BOD,” and further informing Deutsch that ��I have a shareholder who is will[ing] [sic] to have their name as the lead” but that he had not yet been able to find someone to finance the effort.

• In June of 2022, Lautz texted Tudor indicating that Lautz could no longer be “the face” of the activist undertaking.
  
  
  
  
  • Lautz followed up several days later asking Tudor “were you able to find someone to be the face of the activist?”

• Days later, the Activist Group learned that Jorgl, who owned no AIM stock, was willing to be the “face” of its endeavor. Chioini texted Rice:
  
  
  
  
  • “[w]e really need to get [Jorgl] b[u]y the shares today every day matters.”
    
    
    
    
  • “Try to get him to do it in the next 40 minutes. It’s probably very important. And I’ll jump on the phone with them and talk to the guy if he wants.”
    
    
    
    
  • “I [am] burning a Cuban limited edition Hoyo de Monterrey [cigar] sitting on my dock in the 87 [degree] heat under the sun. The same thing we’re going to do when we celebrate winning board seats taking control of the company.”
    
    

• Finally, discovery revealed that Michael Xirinachs – whose involvement Jorgl did not initially disclose – was actively involved with the activist effort for months. Xirinachs recently pled guilty to criminal charges of wire fraud relating to fraudulent securities trading and promotion and material misrepresentations to investors and misuse of funds. According to the Activist Group’s definitive proxy statement, Xirinachs was sentenced by a federal court on June 13, 2022 to three years of probation and ordered to pay hundreds of thousands of dollars in restitution.
  
  
  
  
  • Email communications produced in discovery show that Xirinachs began discussing AIM with the Activist Group as early as April 29, 2022, less than two months before his sentencing for wire fraud in connection with penny stock manipulation. Xirinachs subsequently agreed to fund the effort to take over AIM.
    
    
    
    
  • Xirinachs was deeply involved in the scheme nearly two months before the Activist Group identified Jorgl to serve as the “face” of the efforts.
    
    
    
    
  • Initially, the Activist Group tried to construct a fiction that an entity called River Rock Advisors was funding the nomination efforts and stated in a press release that River Rock would be participating in the solicitation. But discovery revealed that River Rock had no funds and that Xirinachs is secretly funding some or all of the group’s efforts, leading to the Activist Group having to finally disclose Xirinachs’ role in its proxy statement.

The Activist Group Has Nefarious Intentions

Perhaps most damning for the Activist Group’s campaign is that discovery has revealed it is hiding its true intentions for the Company.

The Company received additional evidence in the litigation that the Activist Group includes other undisclosed AIM shareholders with significant ownership in likely violation of the federal securities laws. This evidence included handwritten notes belonging to Ted Kellner that, in reference to 2022 conversations with Todd Deutsch and others, estimate that their undisclosed group had significant aggregate beneficial ownership over AIM shares:

• “Thought collectively we had 20 percent”
  
  
  
  
• “What do we own? 15 to 18 percent. Franz Tudor? Who wrote this [memo on AIM]? Franz”

With this context, it is no surprise that despite owning just 1,000 shares acquired for $870, Jorgl and the members of the Activist Group that have been disclosed have said they will spend nearly 1,000 times that (approximately $850,000) on its campaign to take control of the Board.

As to what the Activist Group might do if it is successful, Xirinachs stated in a July 2022 email to Chioini:

• “The way I hope this all plays out is we get control of AIM … we continue to look for opportunities to either acquire, (to spin off at a later time), license technology, or possibly merge with.”
  
  

• Xirinachs twice refers to Jorgl’s nominees as “our slate.”

The AIM Board Has Successfully Executed on a Multi-Year Turnaround Plan and the Company Has Significant Momentum

The incumbent AIM Board has overseen the Company’s successful efforts to overcome multiple obstacles, keep the lights on when there was no money, improve its financial condition and set the Company on a path towards long-term shareholder value creation.

• In 2015, AIM was in crisis: cash was extremely low, the NYSE threatened to delist AIM’s stock because it was trading under $0.20 per share, and auditors questioned AIM’s going-concern status. The Company’s supply of its primary drug, Ampligen, was perilously low and there were no clinical trials in the works.

• Then, in 2016, the current members of the Board put in place a plan to contain expenses, including through reworking and in numerous instances deferring executive and director compensation, and to increase cash reserves to manufacture Ampligen. The turnaround plan has been successful. Ampligen is now in adequate supply, AIM is conducting several clinical trials and results to date are promising, establishing the drug’s potential in multiple applications.

• We have achieved multiple potentially game-changing clinical and regulatory milestones this year, and expect this positive momentum to continue throughout the rest of 2022 and into next year. These include the following:
  
  
  
  
  • Extremely positive data from a single-center named patient program was published in March 2022. The manuscript titled, “Rintatolimod (Ampligen®) enhances numbers of peripheral B cells and is associated with longer survival in patients with locally advanced and metastasized pancreatic cancer pre-treated with FOLFIRINOX: a single-center named patient program,” was published in the peer-reviewed journal, Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer.
    
    
    
    
  • Presented positive data in an abstract at the American Association for Cancer Research (AACR) Annual Meeting 2022 which shows significant survival advantage when Ampligen is combined with Keytruda in advanced recurrent ovarian cancer.
    
    
    
    
  • We received notification from the U.S. Food and Drug Administration (“FDA”) that the FDA’s Clinical Hold on AIM’s investigational new drug (“IND”) application for a Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer (“AMP-270”) had been lifted and the Company may proceed with the study.
    
    
    
    
  • On July 28, 2022, we reported positive preliminary pilot study data from our ongoing Expanded Access Program (“AMP-511”) evaluating Ampligen in patients with chronic fatigue symptoms following COVID infections (a form of “Long COVID”).
    
    
    
    
  • Subsequent to the positive results in AMP-511, on October 12, 2022, we reported that the FDA had authorized AIM to proceed with a Phase 2 study evaluating Ampligen as a therapeutic for patients with post-COVID conditions (“AMP-518”).
    
    

• Your Board has the right experience, skill sets and deep knowledge of the Company and its drug candidates to continue overseeing the successful execution of our strategy to deliver therapies for patients and value for our shareholders.
  
  
  
  
  • Stewart L. Appelrouth is a certified public accountant with over 40 years of accounting and audit experience. He serves as head of the Board’s audit committee and brings important leadership, industry, financial and regulatory expertise, including having served as a FINRA Arbitrator.
    
    
    
    
  • Thomas K. Equels, M.S., J.D., Executive Vice Chairman, Chief Executive Officer and President, has decades of experience as a practicing attorney specializing in complex business litigation. He also has extensive experience in clinical trial design and development, creating intellectual property concepts, and in financing drug development – as well as industry legal experience.
    
    
    
    
  • Dr. William M. Mitchell, Chairman, has extensive medical industry experience, including as a Professor of Pathology at Vanderbilt University School of Medicine, a board-certified physician and a former member of the Board of Directors of Chronix Biomedical, a company involved in next generation DNA sequencing for medical diagnostics. Dr. Mitchell is the inventor of record on numerous U.S. and international patents and is experienced in regulatory affairs through filings with the FDA.

We appreciate your support and investment in the Company. As described above, the Activist Group’s actions have created much noise and distraction around this year’s Annual Meeting. We urge you to listen to the facts and recognize that the Activist Group’s best interests are not aligned with yours.

Please ignore any proxy materials you receive from the Activist Group and vote on the Company’s WHITE proxy card for your current highly qualified directors to protect your investment.

Sincerely,

The AIM ImmunoTech Board of Directors

WE URGE YOU TO COMPLETE, DATE, AND SIGN THE ENCLOSED WHITE PROXY CARD AND MAIL IT PROMPTLY IN THE POSTAGE-PAID ENVELOPE PROVIDED, OR VOTE BY TELEPHONE OR THE INTERNET AS INSTRUCTED ON THE WHITE PROXY CARD, WHETHER OR NOT YOU PLAN TO ATTEND THE ANNUAL MEETING.

THE BOARD RECOMMENDS A VOTE “FOR ALL” OF OUR BOARD’S NOMINEES

(STEWART L. APPELROUTH, THOMAS K. EQUELS AND WILLIAM M. MITCHELL)

ON PROPOSAL 1 USING THE ENCLOSED WHITE PROXY CARD.

If you have any questions or need assistance voting, please contact the Company’s proxy solicitor Morrow Sodali LLC (“Morrow Sodali”) using the below information.

Morrow Sodali

509 Madison Avenue

Suite 1206

New York, NY 10022

Banks and Brokers Call: (203) 658-9400

Shareholders Call Toll Free: (800) 662-5200

E-mail: AIM@investor.morrowsodali.com

About AIM ImmunoTech Inc.

AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders, and viral diseases, including COVID-19. The Company’s lead product, Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity being developed for globally important cancers, viral diseases and disorders of the immune system.

Ampligen is currently being used as a monotherapy to treat pancreatic cancer patients in an Early Access Program (EAP) approved by the Inspectorate of Healthcare in the Netherlands at Erasmus Medical Center and AIM plans to initiate a Phase 2 clinical study in 2022. The Company also has multiple ongoing clinical trials to evaluate Ampligen as a combinational therapy for the treatment of a variety of solid tumor types both underway and planned at major cancer research centers. Additionally, Ampligen is approved in Argentina for the treatment of severe chronic fatigue syndrome (CFS) and is currently being evaluated in many aspects of SARS-CoV-2/COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and Post COVID Conditions.

For more information, please visit aimimmuno.com and connect with the Company on Twitter, LinkedIn, and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221026006042/en/